ArticleScience advances2023
Transformable nano-antibiotics for mechanotherapy and immune activation against drug-resistant Gram-negative bacteria.
Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- Stimuli-responsive structural transformation of adaptive peptide nanomaterials toward biomedical applications.Materials today. Bio · 2026Review
- Advanced Nanomaterials for Chronic Wounds: M.O.I.S.T. Concept-Driven Design Strategy.Advanced healthcare materials · 2026Review
- Nanoantibiotics: peroxidase-mimicking bimetallic Au-Pt nanorods for antibacterial and antibiofilm applications.RSC advances · 2026Article
- An inhalable gallium-polyphenol nanoparticle blocks bacterial electron transport chain and signal transduction for anti-biofilm therapy.Bioactive materials · 2026Article
- The structures and functions of Salmonella outer membrane.Archives of microbiology · 2026Review
- High-entropy alloy Janus artificial enzymes for pH-gated sequential redox therapy of drug-resistant bacterial infection.Nature communications · 2026Article
- Designing the Next Generation of Biomaterials through Nanoengineering.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Nucleotide coordinated polymers, a ROS-based immunomodulatory antimicrobial, doubly killBioactive materials · 2025Article
- Antibiotics Trigger Host Innate Immune Response via Microbiota-Brain Communication inInternational journal of molecular sciences · 2024Article
- Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dearth of antibiotic candidates against Gram-negative bacteria and the rise of antibiotic resistance create a global health concern. The challenge lies in the unique Gram-negative bacterial outer membrane that provides the impermeable barrier for antibiotics and sequesters antigen presentation. We designed a transformable nano-antibiotics (TNA) that can transform from nontoxic nanoparticles to bactericidal nanofibrils with reasonable rigidity (Young's modulus, 21.6 ± 5.9 MPa) after targeting β-barrel assembly machine A (BamA) and lipid polysaccharides (LPSs) of Gram-negative bacteria. After morphological transformation, the TNA can penetrate and damage the bacterial envelope, disrupt electron transport and multiple conserved biosynthetic and metabolic pathways, burst bacterial antigen release from the outer membrane, and subsequently activate the innate and adaptive immunity. TNA kills Gram-negative bacteria in vitro and in vivo with undetectable resistance through multiple bactericidal modes of action. TNA treatment-induced vaccination results in rapid and long-lasting immune responses, protecting against lethal reinfections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.